Purpose: The reliability of microarray-based cancer prognosis is questioned by Michiels et al. They reanalyzed seven studies published in the prominent journals as successful stories of microarray-based cancer prognosis and concluded that the originally reported assessments are overoptimistic. We set to investigate the reality of microarrays for predicting cancer prognosis by using the same data sets with commonly accepted data analysis approaches.
Nonetheless, optimism for microarray applications in diverse fields of science and medicine has suffered both perceptual and real setbacks as recent publications in prominent journals seriously challenged their reliability. Criticism was largely on the grounds of general nonreproducibility of gene signatures (15) (16) (17) , and the inability to replicate results in terms of significant genes from experiments in different laboratories and from different experimental platforms. The concerns extended also to the use of microarrays in determining biomarkers for cancer prognosis (18, 19) . Michiels and coworkers (19) reanalyzed seven data sets notable for prominence as success stories of using DNA microarrays for cancer prognosis, concluding that published claims were overoptimistic. This review has been widely cited (over 470 times at the time of this writing, based on Google scholar searching), thereby surely becoming a point of reference for application of DNA microarrays in cancer prognosis.
The Michiels et al.'s (19) review incorporated a correlation-based feature selection (top 50 genes were used) and split sample validation strategies into a nearest-centroid classifier development to assess the validity of the microarray-based classifiers for cancer prognosis. Specifically, they used multiple training-test sample splits with a balanced class labels for each training set and a repeated random resampling in each defined split to derive the empirical distribution of test set error as a putative confidence interval for assessing the prediction accuracy. They plotted those putative 95% limits as a function of the training set size to determine that the classifier was no better than chance if these limits did not exclude 0.5. They found that classifiers for five of seven cancer prognosis data sets yielded results no better than the random chance. In addition, the repeated random sampling resulted in unstable (i.e., widely varying) lists of signature genes among classifiers from different random splits of the same data set, indicating the published classifiers for cancer prognosis that are not valid.
There are two major concerns about the validity of Michiels et al.'s (19) study and resulting conclusions. First, Michiels et al.'s (19) reanalyses applied a single and specific combination of gene selection rule (Pearson's correlation), validation strategy (split sample), and classifier (nearest-centroid prediction rule). The concern is whether their findings can be generalized if other commonly wellreceived feature selection rules, validation strategies, and classification methods are used. Consequently, we reanalyzed these seven data sets using several other popular approaches as a parameter study summarized in Table 1 . We found that although different signature genes might result in similar classification accuracy, the stability of signature genes was largely dependent on the choice of feature selection rules. Using cross-validation, instead of split sample validation adopted by Michiels et al. (19) , six of seven studies actually resulted in prediction models better than random predictions. Finally, the choice of classification methods has a relatively small effect on the performance of a classifier.
The second concern was about the significance test that was used to evaluate whether prediction accuracy was better than chance (i.e., chance correlation). It has been suggested that confidence intervals derived from the split sample approach is only effective when both training and test sets are sufficiently large (20) . Because the studied seven data sets are of limited sample sizes, which is common in practice, the binomial intervals based on split sample used by Michiels et al. (19) do not necessarily have sufficient power to assess the chance correlation. Thus, in the current study, a permutation test was used (21) , where the null distribution (determined by randomly shuffling the class labels for 2,000 times followed by the 5-fold cross-validation on each permutation) was compared with the true distribution (repeating the 5-fold cross-validation for 2,000 times). We found that, based on a conservative estimation, at least four of seven data sets yielded classifiers performing better than chance.
Translational Relevance
Microarray-based cancer diagnostic and prognostic tests have been intensively investigated during the past 10 years. However, their utilities have been continually questioned largely due to inconsistent findings from different statistical methods used to assess the tests' predictivity. We reanalyzed seven studies published in the prominent journals using DNA microarrays for cancer prognosis and concluded that in contrary to the findings by Michiels et al., the use of DNA microarrays for cancer prognosis can be demonstrated. Our work presents an objective picture on the applications of microarray-based molecular signatures for cancer research and clinical practices. The work also highlights the importance for the research community to reach consensus on the best practices of developing and validating microarray-based classifiers for clinical application. We conclude that the microarray-based classifiers for cancer prognosis can be demonstrated. We stressed that caution should be exercised when a general conclusion is withdrawn based on a single statistical practice without alternative validation, which can leave a false impression and pessimistic perspective for emerging biomarker methodologies to advance cancer research. The work also highlights the importance for the research community to reach consensus on the best practices of developing and validating microarray-based classifiers for clinical application.
Materials and Methods

Data sets
The same seven microarray data sets used by Michiels et al. (19) were reanalyzed in this study. These seven data sets are the largest microarray cancer prognosis studies published before April 2003 (10) . The sample size varies from 60 to 240 and the prevalence is between 14% and 58% ( Table 2) . More information about these data sets can be found from the table and supplementary materials provided by Michiels et al. (19) . This study reproduced the data preprocessing (e.g., gene filtering) conducted by Michiels et al. (19) on all seven data sets.
Data analysis methods
The parameter study and permutation test were conducted in this re-evaluation.
Parameter study. The analyses were done as a parameter study by dividing classifier development and validation into three parts as shown in Table 1 . For each of the seven data sets, either feature selection rule, classifier method, or validation strategy was varied, whereas the other two parts were done in the same way as Michiels et al. (19) . Specifically as follows:
• Part A of the study assessed the effect of different gene selection rules on prediction accuracy and signature stability. Several commonly used feature selection methods were first used to select the top 50 features based on: (a) P value criterion from the Student's t test, (b) fold change (FC), (c) FC ranking after P < 0.05 filtering, and (d) P value ranking after FC > 1.5 filtering (for the two 2-color array data sets in studies 2 and 4, the threshold of FC is 1.2). Then, the same classification method (nearest-centroid predictor) and validation strategy (split sample) as used by Michiels et al. (19) were used.
• Part B varied the validation strategy while using the same feature selection (i.e., Pearson's correlation) and classification method (i.e., nearest-centroid) as Michiels et al. (19) . Leave-one-out (LOO) crossvalidation (CV), 5-fold CV, and 10-fold CV were used. Complete cross-validation was done, which repeats the feature selection in each of the cross-validation training sets to avoid feature selection bias. Michiels et al.'s (19) methods were replicated for comparison purposes.
• In part C, we investigated two additional classification methods, i.e., KNN (K = 5) and SVM, in addition to the nearest-centroid prediction rule, while retaining Michiels et al.'s (19) feature selection method and validation strategy.
Each validation strategy was repeated 500 times except LOO. For the split sample validation strategy, the training set was forced to be balanced, i.e., the sample sizes of two classes in each training set are equal. The sample size of training set was incrementally increased from 10 to a maximum with a step of two, as was done by Michiels et al. (19) .
Permutation test. A permutation test was used with cross-validation to assess whether a classifier performs better than chance (i.e., chance correlation; ref. 21). First, 2,000 pseudo data sets were generated, where the subjects' class labels were randomly scrambled. Next, a 5-fold cross-validation is conducted for each pseudo data set to generate a null distribution, i.e., the distribution of classification accuracy from all classifiers developed on all the pseudo data sets. The null distribution was then compared with the distribution of 2,000 runs of 5-fold cross-validation results derived from the real data set. The degree of chance correlation was estimated using t test and Cohen's d (22). Cohen's d is an effect size and often used in conjunction with t test to indicate the standardized difference between two means. The effect size assesses a non-null hypothesis that expects to detect, where the effect size = 0.2 is indicative of a small effect, whereas 0.5 and 0.8 are medium and large effect size, respectively. In this study, Cohen's d assesses the effect size between two distributions derived from the pseudo data sets and the real data set, respectively.
Results
Parameter study
Part A: the effects of feature selection rules. The misclassification rate as a function of the training set size for different feature selection rules is shown in Fig. 1 . All five feature selection rules yielded similar misclassification rates, indicating only minor effects among the five feature selection rules on classifier prediction accuracy. However, the five feature selection rules led to markedly different numbers of signature genes commonly selected by different classifiers during resampling, a characteristic that Michiels et al. (19) call instability. As shown in Table 2 , with Michiels et al.'s (19) analysis approach (i.e., Pearson correlation) feature selection by FC and FC (P < 0.05) results markedly increase in common genes compared to the P-value driven methods [i.e., P and P (FC > 1.5)]. Thus, whereas prediction accuracy is essentially unaffected by feature selection rules, gene stability is dramatically increased by feature selection using the FCdriven methods.
Part B: the effect of validation strategies. Figure 2 compares plots of misclassification rate versus training set size for split sample and the three different cross-validation strategies (i.e., LOO, 5-fold cross-validation, and 10-fold cross-validation). The same criterion by Michiels et al. (19) was used to assess the validity of a classifier where the upper 95% confidence limit as a function of the training set size concludes that the classifier is no better than chance if the limit is larger than 0.5. Only study 8 has the upper 95% confidence limit of misclassification rates clearly larger than 0.5 when cross-validation methods were used, indicating that six of the seven studies could perform better than chance. This result is very different from the Michiels et al.'s (19) findings that only two of the seven studies (i.e., studies 3 and 4) classified patients better than chance based on split sample validation.
Part C: the effect of the choice of classification methods. Figure 3 plots the misclassification rate as a function of the training set size for three classification methods, SVM, KNN, and nearest centroid [used by Michiels et al. (19) ]. On balance, choice of classification methods is seen to minimally affect the prediction accuracy. For studies 2 and 8, KNN performed slightly better, whereas SVM achieved slightly worse classification in study 3. Figure 4 shows the results of a most well-received permutation test to assess whether a classifier performs better than chance (i.e., chance correlation; ref. 21) . Except for studies 3 and 8, the other five studies have narrower distributions of prediction accuracy for the real data sets compared with those from the pseudo data sets with clear separation, indicating that these five studies yielded classifiers better than chance. Using the Cohen's d to assess the effect size, i.e., the inherent predictability, four data sets (studies 2, 4, 6/7, and 9) show a large effect size; two (studies 5 and 8) show medium effect size; and only study 3 shows a very small effect size. Interestingly, study 3, which showed the worst performance against chance in the permutation study, is one of only two data sets (studies 3 and 4) considered better than chance in the Michiels et al.'s (19) review. Our results raise a serious concern about using the binomial interval based on split sample to assess the validity of a classifier, as previously pointed out by others (20) . Figure 4 also implies that chance correlation is dependent on the quality of a data set, and thus affects stability of signature genes. As depicted in Fig. 5 , a linear correlation was observed between the number of common genes based on the FC (P < 0.05) feature selection rule ( Table 2 , column 6) and Cohen's d (Fig. 4) across seven data sets, indicating that the degree of predictability of a data set positively correlates with the stability in the signature genes used for the classifier.
Permutation test
Discussion
The seven cancer prognosis data sets analyzed by Michiels et al. (19) were reevaluated, both replicating their work by expanding its scope to include different gene selection rules, validation strategies, and classification methods, and applying a permutation test as an alternative approach to assess the robustness and reliability of classifiers derived from these seven data sets. Our results and conclusions differ substantially compared with those of Michiels et al. (19) .
Reproducibility of significant genes from a microarray experiment is a clearly desirable characteristic in class comparison (23) because different genes might lead to different biological interpretations. As depicted in Fig. 1 , comparable prediction accuracy is obtained for cancer prognosis with different feature selection rules, but the degree by which genes are common in classifiers strongly differs with feature selection rules ( Table 2 ). Many more features are in common between signature genes when a FC-based rule is used to select features than when Pearson's correlation coefficient or a simple t test is used. The findings are consistent with the results reported by the first phase of the MicroArray Quality Control project (24) (25) (26) . Thus, if stability is important (as it usually does because a consistent biology can be drawn from the signature genes) together with prediction accuracy, the magnitude of the differential expression with a loose P value cutoff (e.g., P = 0.05) is the preferred metric for selecting features over the P value from statistical tests.
It is arguable that a classifier only needs to be accurate in prediction, and the stability of signature genes is a secondary concern. However, the dependency between prediction accuracy and stability of signature genes is not clear. Determined by both prediction accuracy and stability of signature genes, the most robust classifier was derived from study 4, whereas study 3 resulted in the worst classifier. It seems that the stability of signature genes correlates with the degree of the predictability of the cancer prognosis data set (Fig. 5) . However, it is important to note that because of the high correlation of expression profiles between genes, classifiers using completely different subsets of genes may have the same level of prediction accuracy. For example, if a P value is used for feature selection, it is entirely possible that different training sets could yield gene signatures with little or no common genes, although all genes might be true positives, and both classifiers are able to make equally accurate predictions. In this case, there would be two good solutions to the same mathematical problem. Therefore, there is no substantial evidence to support criticizing gene expression modeling on the sole ground of lacking the reproducibility of signature genes (11) .
Both cross-validation and split sample validation are widely accepted in the research community as nonbiased internal validation methodologies (27, 28) and both have been extensively used in microarray applications. The results reported here for cross-validation indicate that the published cancer prognosis classifiers perform better than chance for six of seven data sets, in contrast with the two of seven reported by Michiels et al. (19) with split sample validation. Figure 2 shows that the mean value of cross-validation results was almost the same as for the split sample validation, indicating that both methods achieved a similar estimation of prediction accuracy. However, cross-validation gave a comparatively smaller SD than the split sample method, and is the primary reason for the different conclusions. The exact reasons why the two methods differ is beyond the scope of this article, but examination of the reasons is clearly warranted, as is further work needed in determining the most appropriate way of validating microarray-based classifiers.
A large number of classification methods has been used for microarray applications, but scientific consensus on the best choices among them does not exist yet. Three different classification methods were used in the parameter study, namely KNN, nearest centroid, and SVM. Overall, for the same data set, the classifiers derived from the three methods gave comparable accuracy, with only minor differences observed for a couple of data sets.
Testing whether a classifier performs better than chance (i.e., chance correlation) is highly desirable. Testing becomes increasingly imperative for smaller training sets, such as those used in this study. However, the issues of computing valid confidence intervals to assess chance correlation are complicated (20, 28) . The binomial interval, based on the spilt sample used by Michiels et al. (19) , is the lack of power for assessing the prediction error. For example, as the size of the training set increases, the size of the test set decreases and the binomial error variance on the test set increases. For the smallest training sets, the binomial error variance is smaller but the model may be much poorer than the model that can be developed on the full data set; hence, the interval estimate is biased. For these reasons, a permutation test was implemented to provide an objective view on the chance correlation. The permutation test showed that conservatively, a minimum of four of seven data sets yielded prediction accuracy better than chance.
The permutation test also revealed that a valid model cannot be developed for study 3, in contrary to Michiels et al.'s (19) conclusion that study 3 is one of the only two data sets (studies 3 and 4) of seven that yields prediction accuracy better than chance. Study 3 has an unbalanced class distribution with only 14% positive cases ( Table 2) . In other words, the naïve prediction with assigning every sample into the negative class will result in the prediction accuracy of 86%. This indicates that the criteria applied by Michiels et al. (19) based on 50% prediction accuracy as a threshold (i.e., the horizontal line in Figs. 1 and 2 ) to determine whether a classifier is performing better than chance is not appropriate for a skewed data set.
Conclusion
Our parameter study exploring in a larger parameter space confirms the need for caution when inferring the validity of a classifier or the lack of it. Furthermore, our permutation test shows that the confidence interval used by Michiels et al. (19) for assessing the validity of a classifier is not rigorous and robust. Our results suggest that a better understanding of how best to assess classifiers in cancer prognostics is needed before generalized conclusions can be rendered. The utility of microarrays and other high-throughput technologies has been shown in clinical applications and safety assessment. It seems apparent that the excitement surrounding microarrays in general and the rush to publish in this area in particular have resulted in published studies that were not adequately validated. Publications such as Michiels et al.'s (19) have brought widespread attention to the early and perhaps premature studies that made unsupportable inferences. However, caution is also warranted in indicting microarrays in a broad way as unreliable, when so much work remains to be done in understanding how best to analyze such complex data and the extension of assessing the utility of a classifier derived from such data. Because of the importance of microarray-based classifiers in clinical applications and safety assessments, the MicroArray Quality Control project entered a second phase of comparing different approaches to the development and validation of microarray-based classifiers for use in clinical practices (29) .
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